These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16987837)

  • 1. Connective tissue diseases: evaluation of clinical response.
    Fischer-Betz R; Schneider M
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii5-7. PubMed ID: 16987837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity.
    American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria
    Arthritis Rheum; 2004 Nov; 50(11):3418-26. PubMed ID: 15529383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement.
    Ruperto N; Ravelli A; Oliveira S; Alessio M; Mihaylova D; Pasic S; Cortis E; Apaz M; Burgos-Vargas R; Kanakoudi-Tsakalidou F; Norambuena X; Corona F; Gerloni V; Hagelberg S; Aggarwal A; Dolezalova P; Saad CM; Bae SC; Vesely R; Avcin T; Foster H; Duarte C; Herlin T; Horneff G; Lepore L; van Rossum M; Trail L; Pistorio A; Andersson-Gäre B; Giannini EH; Martini A;
    Arthritis Rheum; 2006 Jun; 55(3):355-63. PubMed ID: 16739203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set.
    Ruperto N; Ravelli A; Cuttica R; Espada G; Ozen S; Porras O; Sztajnbok F; Falcini F; Kasapcopur O; Venning H; Bica B; Merino R; Coto C; Ros J; Susic G; Gamir ML; Minden K; See Y; Uziel Y; Mukamel M; Riley P; Zulian F; Olivieri AN; Cimaz R; Girschick H; Rumba I; Cavuto S; Pistorio A; Lovell DJ; Martini A; ;
    Arthritis Rheum; 2005 Sep; 52(9):2854-64. PubMed ID: 16142708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
    Mok CC; Ho LY; Cheung MY; Yu KL; To CH
    Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Undifferentiated systemic connective tissue disease-"overlap' in Zimbabwe.
    Lutalo SK; Glavintcheva I
    Cent Afr J Med; 1996 Jun; 42(6):166-9. PubMed ID: 8870313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Paediatric Rheumatology International Trials Organization (PRINTO).
    Ruperto N; Bazso A; Ravelli A; Malattia C; Filocamo G; Pistorio A; Rodriguez Lozano AL; Viola S; Martini A;
    Lupus; 2007; 16(8):670-6. PubMed ID: 17711906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual.
    Vilá LM; Alarcón GS; McGwin G; Bastian HM; Fessler BJ; Reveille JD;
    Arthritis Rheum; 2006 Oct; 55(5):799-806. PubMed ID: 17013840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriasis assessment tools in clinical trials.
    Feldman SR; Krueger GG
    Ann Rheum Dis; 2005 Mar; 64 Suppl 2(Suppl 2):ii65-8; discussion ii69-73. PubMed ID: 15708941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring clinical response and remission in juvenile idiopathic arthritis.
    Ringold S; Wallace CA
    Curr Opin Rheumatol; 2007 Sep; 19(5):471-6. PubMed ID: 17762613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A database for systemic lupus erythematosus and systemic connective tissue disorders.
    Edworthy SM
    Rheum Dis Clin North Am; 1995 May; 21(2):501-25. PubMed ID: 7631041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Look--but also listen! ReQuest: an essay on a new validated scale to assess the outcome of GERD treatment.
    Bardhan KD; Berghöfer P
    Digestion; 2007; 75 Suppl 1():87-100. PubMed ID: 17489037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of disease activity and quality of life in systemic lupus erythematosus - New aspects.
    Yee CS; McElhone K; Teh LS; Gordon C
    Best Pract Res Clin Rheumatol; 2009 Aug; 23(4):457-67. PubMed ID: 19591777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of response criteria for clinical trials of sarcoma treatment.
    Schuetze SM; Baker LH; Benjamin RS; Canetta R
    Oncologist; 2008; 13 Suppl 2():32-40. PubMed ID: 18434637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing single joints in arthritis clinical trials.
    Giles JT; Mease P; Boers M; Bresnihan B; Conaghan PG; Heald A; Maksymowych WP; Maillefert JF; Simon L; Tsuji W; Wakefield R; Woodworth T; Schumacher HR; Bingham CO
    J Rheumatol; 2007 Mar; 34(3):641-7. PubMed ID: 17343312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus.
    Gordon C; Bertsias G; Ioannidis JP; Boletis J; Bombardieri S; Cervera R; Dostál C; Font J; Gilboe IM; Houssiau F; Huizinga TW; Isenberg D; Kallenberg CG; Khamashta MA; Piette JC; Schneider M; Smolen JS; Sturfelt G; Tincani A; Van Vollenhoven R; Boumpas DT
    Ann Rheum Dis; 2009 Apr; 68(4):470-6. PubMed ID: 18388158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life in systemic lupus erythematosus.
    Panopalis P; Clarke AE
    Clin Dev Immunol; 2006; 13(2-4):321-4. PubMed ID: 17162373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Greater accrual damage in late-onset systemic lupus erythematosus: a long-term follow-up study.
    Appenzeller S; Pereira DA; Costallat LT
    Lupus; 2008 Nov; 17(11):1023-8. PubMed ID: 18852227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between health-related quality of life and SLE activity and damage in children over time.
    Moorthy LN; Peterson MG; Hassett AL; Baratelli M; Chalom EC; Hashkes PJ; Hong S; Reiff A; Lehman TJ
    Lupus; 2009 Jun; 18(7):622-9. PubMed ID: 19433463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity, damage and outcome in systemic vasculitis.
    Carruthers D; Bacon P
    Best Pract Res Clin Rheumatol; 2001 Jun; 15(2):225-38. PubMed ID: 11469819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.